- Home
- APM vs CMND Comparison
APM vs CMND Comparison
Compare APM & CMND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APM
- CMND
- Stock Information
- Founded
- APM 2010
- CMND 2017
- Country
- APM United Kingdom
- CMND Canada
- Employees
- APM N/A
- CMND N/A
- Industry
- APM Biotechnology: Pharmaceutical Preparations
- CMND Biotechnology: Pharmaceutical Preparations
- Sector
- APM Health Care
- CMND Health Care
- Exchange
- APM Nasdaq
- CMND Nasdaq
- Market Cap
- APM 6.1M
- CMND 5.2M
- IPO Year
- APM 2018
- CMND N/A
- Fundamental
- Price
- APM $0.93
- CMND $0.99
- Analyst Decision
- APM
- CMND
- Analyst Count
- APM 0
- CMND 0
- Target Price
- APM N/A
- CMND N/A
- AVG Volume (30 Days)
- APM 137.3K
- CMND 594.4K
- Earning Date
- APM 05-20-2025
- CMND 06-12-2025
- Dividend Yield
- APM N/A
- CMND N/A
- EPS Growth
- APM N/A
- CMND N/A
- EPS
- APM N/A
- CMND N/A
- Revenue
- APM N/A
- CMND N/A
- Revenue This Year
- APM N/A
- CMND N/A
- Revenue Next Year
- APM N/A
- CMND N/A
- P/E Ratio
- APM N/A
- CMND N/A
- Revenue Growth
- APM N/A
- CMND N/A
- 52 Week Low
- APM $0.46
- CMND $0.85
- 52 Week High
- APM $7.49
- CMND $2.30
- Technical
- Relative Strength Index (RSI)
- APM 52.79
- CMND 46.21
- Support Level
- APM $0.80
- CMND $0.94
- Resistance Level
- APM $0.96
- CMND $1.05
- Average True Range (ATR)
- APM 0.07
- CMND 0.06
- MACD
- APM -0.00
- CMND 0.00
- Stochastic Oscillator
- APM 68.36
- CMND 37.45
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.
About CMND Clearmind Medicine Inc.
Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.